

Influence of *interleukin-18* polymorphisms on kidney transplantation outcomes: A meta-analysis

Thanee Eiamsitrakoon^{1,2}, PhuntilaTharabenjasin^{1*}, Noel Pabalan¹, Rungrawee Mongkolrob¹, Aporn Bualuang¹ and Adis Tasanarong^{1,2}

¹ Chulabhorn International College of Medicine, Thammasat University, Cooperative Learning Center, Piyachart 2 Building, 99 Moo 18, Paholyothin Rd., Klong Neung, Klong Luang, Rangsit, Pathumthani 12120 Thailand

² Nephrology Unit, Faculty of Medicine, Thammasat University, 99/209 Moo 18, Paholyothin Rd., Klong Neung, Klong Luang, Rangsit, Pathumthani 12120 Thailand

Thanee Eiamsitrakoon
Email: thaneeiams@gmail.com

Noel Pabalan
Email: noelpabalan@ymail.com

Rungrawee Mongkolrob
Email: scmr303@gmail.com


Aporn Bualuang
Email: tent79@hotmail.com

Adis Tasanarong
Email: adis_tasanarong@hotmail.com

Corresponding author:

Phuntila Tharabenjasin^{1*}
Address correspondence to Phuntila Tharabenjasin, Chulabhorn International College of Medicine, Thammasat University, Cooperative Learning Center, Piyachart 2 Building, 99 Moo 18 Klong Luang, Rangsit, Pathumthani 12120, Thailand

Email: pacezen@yahoo.com
Telephone: (66) 2564-4440-9 Ext 7589 ; (66) 91-959-8915

 orcid.org/0000-0002-4191-2802

Abstract

Aim: Allograft survival post-kidney transplantation (KT) are in large part attributed to genetics, which render the recipient susceptible or protected from allograft rejection. KT studies involving single nucleotide polymorphisms (SNPs) have reported the association of *interleukin-18* (*IL-18*) with KT and its role in allograft rejection. However, the reported outcomes been inconsistent, prompting a meta-analysis to obtain more precise estimates. **Methods:** We posed two hypotheses about the *IL-18* SNPs: their association with KT (H1), and increase or decrease in the risks of allograft rejection (H2). Using standard genetic models, we estimated odds ratios [ORs] and 95% confidence intervals by comparing the *IL-18* genotypes between two groups: (i) patients and controls for H1 (GD: genotype distribution analysis); (ii) rejectors and non-rejectors for H2 (allograft analysis). Multiple comparisons were corrected with the Holm-Bonferroni (HB) test. Subgrouping was ethnicity-based (Asians and Caucasians). Heterogeneity was outlier-treated and robustness of outcomes was sensitivity-treated. **Results:** This meta-analysis generated eight significant outcomes, which HB filtered into four core outcomes, found in the dominant/codominant models. Two of the four were in GD, indicating associations of the *IL-18* SNPs with KT (ORs 1.34 to 1.39, 95% CIs 1.13-1.70, $P_{HB} = .0007-.004$). The other two were in allograft analysis indicating reduced risk with HB P -values of .03 for overall (OR 0.74, 95% CI 0.56-0.93) and Asian (OR 0.70, 95% CI 0.53-0.92). In contrast to the protected Asian subgroup, Caucasians showed non-significant increased risk (OR 1.20, 95% CI .82-1.75, $P^3 = .35$). Sensitivity treatment conferred robustness to all the core outcomes. **Conclusions:** Overall association of *IL-18* SNPs with KT was significant (up to 1.4-fold) and Asians KT recipients were protected (up to 30%). Enabled by outlier treatment, these findings were supported by non-heterogeneity and robustness. More studies may confirm or modify our findings.

62 **Abbreviations**

63	★	robust (all other significant outcomes were non-robust)
64	✓	significant outcome that survived the Bonferroni correction
65	A	adenine
66	AM	analysis model
67	C	cytosine
68	Co	codominant genetic model
69	CB	Clark-Baudouin
70	CC	homozygous genotype
71	CI	confidence interval
72	Do	dominant genetic model
73	de	decreased risk
74	du	duplicate
75	EH	eliminated heterogeneity
76	Fe	fixed-effects
77	G	guanine
78	GD	genotype distribution
79	GS	gained significance
80	H1	hypothesis 1 (GD analysis)
81	H2	hypothesis 2 (allograft analysis)
82	het	heterogeneity
83	Ho	homozygous genetic model
84	hc	higher in controls
85	hp	higher in patients
86	HWE	Hardy-Weinberg Equilibrium
87	<i>IL-18</i>	<i>interleukin-18</i> gene
88	IL-18	interleukin-18 protein
89	in	increased risk
90	KT	kidney transplantation
91	LD	linkage disequilibrium
92	Log OR	logarithm of standardized odds ratio
93	maf	minor allele frequency
94	<i>n</i>	number of studies
95	NRJ	non-rejector
96	OR	odds ratio
97	P^a	P-value for association
98	P^b	P-value for heterogeneity
99	PRO	pre-outlier
100	PSO	post outlier
101	I^2	measure of variability
102	Rc	recessive genetic model
103	[R]	Reference
104	Re	random-effects
105	RH	reduced heterogeneity
106	RJ	rejector
107	RNS	retained non-significance
108	SD	standard deviation
109	SE	standard error
110	sig	significant
111	SNP	single nucleotide polymorphism
112	<i>var</i>	variant
113	<i>wt</i>	wild-type homozygotes
114	<i>wt-var</i>	heterozygote

115

116

117 *Keywords: IL-18* polymorphisms, allograft, kidney transplantation, renal, meta-analysis

118

119

120

121 **1. Introduction**

122
123 The end-stage of renal failure resulting from kidney disease points to kidney transplantation
124 (KT) as the optimal therapeutic choice [1,2]. The transplanted material (allograft) in the
125 recipient is successful only if it is not rejected [3]. Unrejected allografts are expected to
126 perform the functions as normal kidneys. Normal post-KT graft outcomes depend on
127 immunology where variation in immune responses of the recipient is genetically influenced
128 [4]. This variation may help individualize immunosuppressive regimens by identifying alleles
129 that could increase risk or confer protection for immune-mediated complications [5].
130 Cytokines are potent immunomodulatory molecules that mediate the immune response [6].
131 Their production has been shown to be genetically controlled and polymorphisms of many
132 cytokine genes affect their transcriptional activities, resulting in individual variations in
133 cytokine production [7]. Of the cytokine-related factors, interleukin-18 (*IL-18*) has been
134 identified as a post-KT biomarker [8]. Single nucleotide polymorphisms (SNPs) have been
135 reported to be associated with post-KT outcomes [9]. Studies of *IL-18* SNP associations with
136 KT outcomes have promoted better understanding of renal disease immunology, providing
137 greater insight into the biology of KT. However, the primary study conclusions have varied in
138 their degree of concurrence. A meta-analysis addressing this variation may yield clearer
139 estimates of the role of *IL-18* SNPs in KT outcomes. In this meta-analysis, we operated on
140 two hypotheses about the *IL-18* SNPs, their association with KT (H1), and increase or
141 decrease in the risks of AR (H2). In H1, we examine genotype distribution (GD) between
142 patients and healthy controls. In H2 allograft analysis, we compare rejector (RJ) with non-
143 rejector (NRJ) patients. Outcomes from this this might provide useful clinical information for
144 the genetics of KT.

145
146
147
148

149 **2. Methods**

150

151 **Selection of studies**

152 We searched MEDLINE using PubMed, Google Scholar and Science Direct for association

153 studies as of September 24, 2019. The terms used were “*interleukin*”, “*IL-18*”, “*cytokine*”,

154 “*polymorphism*”, “*allograft*” and “*renal transplantation*” as medical subject heading and text.

155 References cited in the retrieved articles were also screened manually to identify additional

156 eligible studies. In cases of duplicate articles, we selected the one with a later date of

157 publication. Inclusion criteria were (1) case–control design evaluating the association

158 between *IL-18* polymorphisms and KT outcomes. (2) *IL-18* genotype frequencies that

159 compare KT patients and healthy controls, NR and NRJ. (3) Sufficient genotype frequency

160 data to enable calculation of the odds ratios (ORs) and 95% confidence intervals (CIs).

161 Exclusion criteria were (1) not involving renal allografts or post-KT outcomes; (2) reviews;

162 (3) not about the *IL-18* polymorphisms and (4) studies whose genotype or allele frequencies

163 were unusable or absent.

164 **SNP groupings**

165 The included articles examined two *IL-18* SNPs, rs187238 and rs1946518, each presented

166 with genotype data (Tables S2 and S3). Observed phenotypic associations have been

167 attributed to the proximity of two SNPs [10,11]. NCI LDLINK (<https://ldlink.nci.nih.gov/>)

168 results shows that the two SNPS are in linkage disequilibrium (LD). LD is the correlation

169 between alleles located near each other [12] which is measured in terms of D' with a value of

170 1 indicating complete LD [13]. Therefore, *IL-18* SNPs (rs187238 and rs1946518) with D'

171 values of 1.00 in this study (Table S1) were combined in the analysis (Tables S2 and S3). The

172 rationale for combining rests on the assumption that SNPs in LD yield similar associations in

173 the phenotype.

174

175 **Data extraction, HWE and methodological quality**

176

177 Two investigators (TE and NP) independently extracted data and arrived at a consensus. The
178 following information was obtained from each publication: first author's name, year of the
179 study, country of origin, ethnicity, age of the subjects in years, *IL-18* SNPs (rs number)
180 (Table 1). Sample sizes as well as genotype data between the RJ and NRJ were also extracted
181 along with calculated outcome of the minor allele frequency (maf) (Tables S2 and S3). The
182 Hardy-Weinberg Equilibrium (HWE) was assessed using the application in
183 <https://ihg.gsf.de/cgi-bin/hw/hwa1.pl>. The Clark-Baudouin (CB) scale was used to evaluate
184 methodological quality of the included studies [14]. CB criteria include *P*-values, statistical
185 power, correction for multiplicity, comparative sample sizes between cases and controls,
186 genotyping methods and the HWE. In this scale, low, moderate and high have scores of < 5,
187 5-6 and ≥ 7 , respectively.

188 **Meta-analysis**

189

190 We estimated ORs and 95 % CIs using two overall approaches: (i) genotype distribution
191 (GD) between cases and healthy controls and (ii) allograft wherein RJ were compared with
192 NRJ. Thus, both were KT outcomes were analysed separately. Calculated pooled ORs for GD
193 were either higher in patients (hp) or higher in controls (hc); in allograft, they were either
194 increased (in) or decreased (de), indicating risk for rejection. Standard genetic modeling was
195 used, wherein we compared the following, (i) recessive (Rc: *wt-wt* versus *wt-var* + *var-var*),
196 (ii) dominant (Do: *wt-wt* + *wt-var* versus *var-var*) and (iii) codominant (Co: *wt* versus *var*)
197 effects. Heterogeneity between studies was estimated with the χ^2 -based Q test [15], with
198 threshold of significance set at $P^b < .10$. Heterogeneity was also quantified with the I^2 statistic
199 which measures variability between studies [16]. Evidence of functional similarities in
200 population features of the studies warranted using the fixed-effects model [17], otherwise the
201 random-effects model [18] was used. Sources of heterogeneity were detected with the

202 Galbraith plot [19] followed by re-analysis (outlier treatment). Of note, outlier treatment
203 dichotomized the comparisons into pre-outlier (PRO) and post-outlier (PSO). Sensitivity
204 analysis, which involves omitting one study at a time and recalculating the pooled OR, was
205 used to test for robustness of the summary effects. The low number of studies precluded
206 assessment of publication bias. Multiple associative outcomes were Holm-Bonferroni (HB)
207 corrected. Data were analysed using Review Manager 5.3 (Cochrane Collaboration, Oxford,
208 England), SIGMAPLOT 11.0 and SIGMASTAT 2.03 (Systat Software, San Jose, CA, USA).

209

210 **3. Results**

211

212 **Search outcomes and study features**

213

214 [Figure 1](#) outlines the study selection process in a PRISMA-sanctioned flowchart (Preferred
215 Reporting Items for Systematic Reviews and Meta-Analyses). Initial search resulted in 39
216 citations, followed by a series of omissions that eventually yielded four articles for inclusion
217 [20-23]. [Table 1](#) shows two Asian [20,21] and two Caucasian [23,22] articles with middle-
218 age profile of the KT subjects (mean \pm SD: 37.8 years \pm 5.9). Three [23,22,21] of the four
219 included articles examined the two *IL-18* polymorphisms (rs187238 and rs1946518).

220 Methodological quality of the component studies was moderate with a mean \pm SD of 6.37 \pm
221 1.24. [Tables S2 and S3](#) show seven studies each for GD and allograft analyses. This meta-
222 analysis followed the PRISMA guidelines ([Table S5](#)).

223 **Meta-analysis outcomes**

224

225 [Table 2](#) delineates the overall pooled ORs by direction of effect, where GDs were higher in
226 patients (*hp*) (OR > 1.00) but decreased risk (*de*) in the allograft analysis (OR < 1.00). The
227 results generated 27 comparisons ([Tables 2-3](#)), eight of which were statistically significant
228 ($P^a < .05$). Of the eight, four withstood the HB correction, which were considered the core
229 findings. Of the four, two were in GD showing *hp* effects in the Do/Co models (OR 1.34-

230 1.39, 95% CIs 1.13 to 1.70, $P_{HB} = .0007-.004$). The other two core outcomes (at HB P -values
231 of .03) were in allograft analysis indicating reduced risk in the Co model, one in the overall
232 (OR 0.73, 95% CI 0.56-0.93) and the other in Asians (OR 0.70, 95% CI 0.53-0.92). This
233 Asian contrasted with the increased risk outcome in Caucasians (OR 1.20, 95% CI 0.82-1.75,
234 $P^a = 0.35$)

235

236 Of note, all four core outcomes were outlier-derived (PSO). The mechanism of outlier
237 treatment for *IL-18* in the Co model of allograft analysis is visualized in Figures 2-4. Figure 2
238 shows the PRO forest plot with a non-significant ($P^a = .48$) and heterogeneous ($P^b = .02$, $I^2 =$
239 60%) pooled effect indicating reduced risk (OR 0.89 95% CI 0.63 to 1.25). The Galbraith
240 plot identified the two studies [22,21] as the sources of heterogeneity (outliers), located above
241 the +2 confidence limit (Figure 3). In Figure 4, the PSO outcome (outliers omitted) shows
242 reduced heterogeneity ($P^b = .16$, $I^2 = 39\%$); reduced risk effect (OR 0.73 95% CI 0.56 to
243 0.93) and gained significance ($P^a = .01$). This operation is numerically summarized in Table
244 2. Sensitivity treatment deemed the core outcomes to be robust.

245

246 4. Discussion

247

248 The main findings of this study showed that *IL-18* SNPs were associated with KT outcomes,
249 more specifically, the allograft analysis indicated reduced risks of rejection. Subgroup
250 analysis identified Asian KT recipients with the *IL-18* SNPs as protected from allograft
251 rejection which contrasted with the increased risk for the Caucasian subgroup. The core status
252 of having withstood HB and robustness of our principal findings underpin the strength of
253 evidence in this study. Furthermore, outlier treatment unraveled significant and non-
254 heterogeneous associations that were not present in the component single-study outcomes.
255 Conflicting outcomes between primary studies may be attributed to their lack of power and

256 small sample sizes. Underpowered outcomes appear to be common in candidate gene studies
257 [24] and are prone to the risk of Type 1 error. In spite of the evidence for associations, the
258 complexity of allograft rejection involves interactions between genetic and non-genetic
259 factors allowing for the possibility of environmental involvement. Gene-gene and gene-
260 environment interactions have been reported to have roles in associations of other
261 polymorphisms with post-KT allograft rejection. One article [21] examined another gene
262 polymorphism (vascular endothelial growth factor (*VEGF*)). All articles acknowledged gene-
263 environment interaction. Addressing gene-gene and gene-environment interactions may help
264 address the pathophysiological significance of *IL-18* in allograft failure post-KT. All the
265 included articles mentioned haplotype analysis with one presenting haplotype data [21].
266 Focus on *IL-18* haplotypes have been suggested for future association studies [9].
267 The crucial role of *IL-18* in kidney physiology lies in its involvement in the filtration,
268 integrity and permeability of the glomerular basement membrane [25]. *IL-18* expression in
269 the renal epithelium might be important in triggering specific immune response manifested as
270 acute graft rejection [26]. Increased *IL-18* production promotes enhanced endothelial
271 permeability and augmented leukocyte migration into the allograft, promoting a clinically
272 recognized rejection episode [21]. A study demonstrated upregulation of *IL-18* production in
273 patients with acute rejection of kidney allograft [26]. Moreover, another study found
274 significantly higher levels of *IL-18* in culture biopsies from patients with acute rejection in
275 comparison to stable KT patients [27]. Urinary *IL-18* has been found to be an early,
276 noninvasive and accurate predictor for dialysis within the first week of KT [28].

277

278 **5. Strengths and limitations**

279

280 Two strengths of our study were: (i) outlier treatment was key to generating significance and
281 reducing heterogeneity; and (ii) subgrouping identified Asians as significantly protected and

282 Caucasians as non-significantly susceptible to allograft rejection. Limitations include: (i) the
283 component studies were underpowered, however, sample sizes were adequate at the
284 aggregate level with 624 cases/634 controls in GD (Table S2) and 147 cases/674 controls in
285 allograft (Table S3). (ii) Genotype distributions of the control population in some studies
286 deviated from the HWE (Tables S2 and S3) and it might be a source of potential bias in our
287 study.

288 6. Conclusions

289 To our knowledge, this is the first meta-analysis with evidence that may render *IL-18* useful
290 as a prognostic marker in allograft rejection post-KT. Additional well-designed studies
291 exploring other parameters may confirm or modify our results in this study.

292

293 Conflict of interest

294 The authors have no conflicts of interest to declare

295

296 Funding

297 None

298

299 Supporting information

300

301	Table S1	LD matrix	DOCX
302	Table S2	Quantitative features GD	DOCX
303	Table S3	Quantitative features Allograft	DOCX
304	Table S4	PRISMA checklist	DOCX

305

306

307

308 References

309

- 310 1. Howard K, Salkeld G, White S, McDonald S, Chadban S, Craig JC, Cass A (2009) The cost-
311 effectiveness of increasing kidney transplantation and home-based dialysis. *Nephrology* 14 (1):123-
312 132. doi:10.1111/j.1440-1797.2008.01073.x
- 313 2. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M,
314 Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N, Eknoyan G (2007) Chronic kidney disease as
315 a global public health problem: approaches and initiatives - a position statement from Kidney Disease
316 Improving Global Outcomes. *Kidney international* 72 (3):247-259. doi:10.1038/sj.ki.5002343
- 317 3. Critchley WR, Fildes JE (2012) Graft rejection - endogenous or allogeneic? *Immunology* 136
318 (2):123-132. doi:10.1111/j.1365-2567.2012.03560.x
- 319 4. Pawlus J, Sierocka A, Tejchman K, Zietek Z, Romanowski M, Pawlik A, Sienko J, Zukowski M,
320 Ciechanowski K, Ostrowski M, Sulikowski T (2014) The impact of interleukin 12B (1188A>C),
321 interleukin 16 (-295T>C), and interleukin 18 (607C>A, 137G>C) gene polymorphisms on long-term
322 renal transplant function and recipient outcomes. *Transplantation proceedings* 46 (6):2079-2082.
323 doi:10.1016/j.transproceed.2014.06.019

- 324 5. Kruger B, Schroppel B, Murphy BT (2008) Genetic polymorphisms and the fate of the transplanted
325 organ. *Transplantation reviews* 22 (2):131-140. doi:10.1016/j.trre.2007.12.002
- 326 6. Seeger H, Lindenmeyer MT, Cohen CD, Jaeckel C, Nelson PJ, Chen J, Edenhofer I, Kozakowski
327 N, Regele H, Boehmig G, Brandt S, Wuethrich RP, Heikenwalder M, Fehr T, Segerer S (2018)
328 Lymphotoxin expression in human and murine renal allografts. *PloS one* 13 (1):e0189396.
329 doi:10.1371/journal.pone.0189396
- 330 7. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW (1997) Effects of a polymorphism in
331 the human tumor necrosis factor alpha promoter on transcriptional activation. *Proceedings of the*
332 *National Academy of Sciences of the United States of America* 94 (7):3195-3199.
333 doi:10.1073/pnas.94.7.3195
- 334 8. Herath S, Erlich J, Au AYM, Endre ZH (2019) Advances in Detection of Kidney Transplant Injury.
335 *Molecular diagnosis & therapy* 23 (3):333-351. doi:10.1007/s40291-019-00396-z
- 336 9. Phelan PJ, Conlon PJ, Sparks MA (2014) Genetic determinants of renal transplant outcome: where
337 do we stand? *Journal of nephrology* 27 (3):247-256. doi:10.1007/s40620-014-0053-4
- 338 10. Liu Y, Lin N, Huang L, Xu Q, Pang G (2007) Genetic polymorphisms of the interleukin-18 gene
339 and risk of prostate cancer. *DNA and cell biology* 26 (8):613-618. doi:10.1089/dna.2007.0600
- 340 11. Wei YS, Lan Y, Liu YG, Tang H, Tang RG, Wang JC (2007) Interleukin-18 gene promoter
341 polymorphisms and the risk of esophageal squamous cell carcinoma. *Acta oncologica* 46 (8):1090-
342 1096. doi:10.1080/02841860701373595
- 343 12. Borecki I (2001) Linkage and Association Studies. In: *Encyclopedia of Life Sciences*. John Wiley
344 & Sons, Ltd,
- 345 13. Lewontin RC (1988) On measures of gametic disequilibrium. *Genetics* 120 (3):849-852
- 346 14. Clark MF, Baudouin SV (2006) A systematic review of the quality of genetic association studies in
347 human sepsis. *Intensive Care Med* 32 (11):1706-1712
- 348 15. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-
349 analyses. *Bmj* 327 (7414):557-560
- 350 16. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. *Stat Med* 21
351 (11):1539-1558
- 352 17. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies
353 of disease. *J Natl Cancer Inst* 22 (4):719-748
- 354 18. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. *Control Clin Trials* 7 (3):177-188
- 355 19. Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical
356 trials. *Stat Med* 7 (8):889-894
- 357 20. Kim CD, Ryu HM, Choi JY, Choi HJ, Cho JH, Park SH, Won DI, Kim YL (2008)
358 Association of G-137C IL-18 promoter polymorphism with acute allograft rejection in renal transplant
359 recipients. *Transplantation* 86 (11):1610-1614. doi:10.1097/TP.0b013e31818870c4
- 360 21. Mittal RD, Srivastava P, Singh V, Jaiswal P, Kapoor R (2011) Association of common variants of
361 vascular endothelial growth factor and interleukin-18 genes with allograft survival in renal transplant
362 recipients of North India. *DNA and cell biology* 30 (5):309-315. doi:10.1089/dna.2010.1138
- 363 22. Kolesar L, Novota P, Krasna E, Slavcev A, Viklicky O, Honsova E, Striz I (2007) Polymorphism of
364 interleukin-18 promoter influences the onset of kidney graft function after transplantation. *Tissue*
365 *antigens* 70 (5):363-368. doi:10.1111/j.1399-0039.2007.00913.x
- 366 23. do Nascimento WG, Cilliao DA, Genre J, Gondim DD, Alves RG, Hassan ND, Lima FP, Pereira
367 MG, Donadi EA, de Oliveira Crispim JC (2014) Genetic polymorphisms of Interleukin-18 are not
368 associated with allograft function in kidney transplant recipients. *Genetics and molecular biology* 37
369 (2):343-349
- 370 24. Dumas-Mallet E, Button KS, Boraud T, Gonon F, Munafo MR (2017) Low statistical power in
371 biomedical science: a review of three human research domains. *Royal Society open science* 4
372 (2):160254. doi:10.1098/rsos.160254
- 373 25. Chen Y, Dawes PT, Packham JC, Matthey DL (2011) Interaction between smoking and
374 polymorphism in the promoter region of the VEGFA gene is associated with ischemic heart disease
375 and myocardial infarction in rheumatoid arthritis. *The Journal of rheumatology* 38 (5):802-809.
376 doi:10.3899/jrheum.101095
- 377 26. Striz I, Krasna E, Honsova E, Lacha J, Petrickova K, Jaresova M, Lodererova A, Bohmova R,
378 Valhova S, Slavcev A, Vitko S (2005) Interleukin 18 (IL-18) upregulation in acute rejection of kidney
379 allograft. *Immunology letters* 99 (1):30-35. doi:10.1016/j.imlet.2005.01.010
- 380 27. de Oliveira JG, Xavier PD, Sampaio SM, Tavares IS, Mendes AA (2002) The synthesis by fine-
381 needle aspiration biopsy cultures of IL-7, IL-16 and IL-18 is significantly associated with acute
382 rejection in kidney transplants. *Nephron* 92 (3):622-628. doi:10.1159/000064106

383 28. Hall IE, Yarlagadda SG, Coca SG, Wang Z, Doshi M, Devarajan P, Han WK, Marcus RJ, Parikh
384 CR (2010) IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation.
385 Journal of the American Society of Nephrology : JASN 21 (1):189-197. doi:10.1681/ASN.2009030264
386

387 TABLE 1 Characteristics of the included studies in *interleukin-18* associations with kidney transplantation outcomes
 388

First author	[R]	Year	Country	Ethnicity	Age (years) mean \pm SD RJ / NRJ	<i>IL-18</i> SNPs	CB
Kim	20	2008	Korea	Asian	33.9 \pm 9.4 / 36.1 \pm 11.1	rs187238	10
Mittal	21	2011	India	Asian	33.2 \pm 12.6 / 38.2 \pm 11.1	rs187238, rs1946518	6
Kolesar	22	2007	Czechlovakia	Caucasian	49.6 (patients)	rs187238, rs1946518	7
do Nascimento	23	2014	Brazil	Caucasian	33.1 \pm 12.4 / 40.5 \pm 13.0	rs187238, rs1946518	7

[R] Reference; *IL-18*,; SD, standard deviation; RJ, rejector; NRJ, non-rejector; SNP, single nucleotide polymorphism; CB, Clark-Baudouin

389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408

409 TABLE 2 Summary outcomes for associations of *interleukin-18* polymorphisms with kidney transplantation outcomes
 410

Test of association									Test of heterogeneity			Test of association				Test of heterogeneity		
<i>n</i>	OR	95% CI	<i>P</i> ^a	<i>P</i> ^b	I ² (%)	AM	<i>n</i>	OR	95% CI	<i>P</i> ^a	<i>P</i> ^b	I ² (%)	AM	Effect of outlier treatment				
PRO									PSO			Sig		Het				
GD				<i>Status</i>					<i>Status</i>									
Rc	7	1.33	0.99-1.79	.06	<i>hp</i>	.12	41	Fe	---	---	---	---	---	---	---	---		
Do	7	1.24	0.93-1.65	.14	<i>hp</i>	.03	57	Re	6	1.39	1.13-1.70	.002 ★	<i>hp</i>	.23	28	Fe	GS	RH
Co	7	1.17	0.96-1.44	.12	<i>hp</i>	.04	54	Re	5	1.34	1.13-1.58	.0007 ★	<i>hp</i>	.22	31	Fe	GS	RH
Allograft				<i>Risk</i>					<i>Risk</i>									
Rc	7	0.84	0.55-1.29	.43	<i>de</i>	.14	38	Fe	---	---	---	---	---	---	---	---	---	
Do	7	0.74	0.55-0.98	.04	<i>de</i>	.46	0	Fe	---	---	---	---	---	---	---	---	---	
Co	7	0.89	0.63-1.25	.48	<i>de</i>	.02	60	Re	5	0.73	0.56-0.93	.01 ★	<i>de</i>	.16	39	Fe	GS	RH

411 GD, genotype distribution; Rc, recessive; Do, dominant; Co, co dominant; *n*, number of studies; OR, odds ratio; CI, confidence interval; *P*^a, *P*-value for association; in, increased
 412 risk; de, decreased risk; hp, higher in patients; *P*^b, *P*-value for heterogeneity (Het); I², measure of variability; AM, analysis model; Re, random-effects; Fe, fixed-effects; PRO,
 413 pre-outlier; PSO, post-outlier; GS, gained Sig; RH, reduced Het; values in bold indicate Sig associations; ★ core outcome.
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429

430 TABLE 3 Subgroup outcomes for associations of *interleukin-18* polymorphisms with kidney transplantation outcomes
431

	PRO								PSO									
	Test of association				Test of heterogeneity				Test of association				Test of heterogeneity					
	<i>n</i>	OR	95% CI	<i>P</i> ^a	<i>P</i> ^b	I ² (%)	AM		<i>n</i>	OR	95% CI	<i>P</i> ^a	<i>P</i> ^b	I ² (%)	AM	Effect of outlier treatment		
GD																		
Asian					<i>Status</i>								<i>Status</i>					
Rc	3	1.47	0.71-3.04	.29	<i>hp</i>	0.09	58	Re	2	1.25	0.76-2.04	.38	<i>hp</i>	.16	49	Fe	RNS	RH
Do	3	1.12	0.71-1.77	.62	<i>hp</i>	0.03	71	Re	2	0.90	0.67-1.22	.51	<i>hc</i>	.16	50	Fe	RNS	RH
Co	3	1.17	0.86-1.60	.32	<i>hp</i>	0.07	63	Re	2	0.99	0.78-1.26	.94	<i>hc</i>	.69	0	Fe	RNS	EH
Caucasian																		
Rc	4	1.09	0.70-1.67	.71	<i>hp</i>	0.25	26	Fe	---	---	---	---	---	---	---	---	---	---
Do	4	1.37	1.04-1.80	.03	<i>hp</i>	0.11	50	Fe	---	---	---	---	---	---	---	---	---	---
Co	4	1.17	0.86-1.61	.32	<i>hp</i>	0.06	60	Re	3	1.32	1.04-1.66	.02	<i>hp</i>	.16	40	Fe	GS	RH
Allograft																		
Asian					<i>Risk</i>								<i>Risk</i>					
Rc	5	0.87	0.38-2.00	.75	<i>de</i>	0.05	58	Re	4	0.62	0.35-1.10	.10	<i>de</i>	.12	49	Fe	RNS	RH
Do	5	0.70	0.50-0.98	.04	<i>de</i>	0.25	25	Fe	---	---	---	---	---	---	---	---	---	---
Co	5	0.78	0.52-1.16	.22	<i>de</i>	0.05	58	Re	4	0.70	0.53-0.92	.01 *	<i>de</i>	.10	52	Fe	GS	RH
Caucasian																		
Rc	2	0.88	0.35-2.20	.78	<i>de</i>	0.82	0	Fe	---	---	---	---	---	---	---	---	---	---
Do	2	0.85	0.50-1.47	.57	<i>de</i>	0.73	0	Fe	---	---	---	---	---	---	---	---	---	---
Co	2	1.20	0.82-1.75	.35	<i>in</i>	0.10	63	Fe	---	---	---	---	---	---	---	---	---	---

432 GD, genotype distribution; Rc, recessive; Do, dominant; Co, co dominant; *n*, number of studies; OR, odds ratio; CI, confidence interval; *P*^a, *P*-value for association; *hp*, higher in
433 patients; *hc*, higher in controls; *in*, increased risk; *de*, decreased risk; *P*^b, *P*-value for heterogeneity (Het); I², measure of variability; AM, analysis model; Re, random-effects; Fe,
434 fixed-effects; PRO, pre-outlier; PSO, post-outlier; GS, gained significance (Sig); RNS, retained non-Sig; RH, reduced Het; EH, eliminated Het; values in bold indicate Sig
435 associations; *core outcome

Interleukin-18 figure captions and legends

Figure 1 Summary flowchart of literature search

Figure 2 Forest plot outcome in the allograft analysis of the codominant model

Diamond denotes the pooled odds ratio (OR) indicating reduced risk (0.89). Squares indicate the OR in each study. m, match. Horizontal lines on either side of each square represent the 95% confidence intervals (CI). The Z test for overall effect was non-significant ($P = .48$). The χ^2 -test shows the presence of heterogeneity ($P = .02$, $I^2 = 60\%$); I^2 , a measure of variability expressed in %

Figure 3 Galbraith plot of the allograft analysis in the codominant model

m, match; Log OR, logarithm of standardized odds ratio; SE, standard error. The two studies above the +2 confidence limit are the outliers.

Figure 4 Forest plot outcome of outlier treatment in the allograft analysis of the codominant model

Diamond denotes the pooled odds ratio (OR) reduced risk (0.73). Squares indicate the OR in each study. m, match. Horizontal lines on either side of each square represent the 95% confidence intervals (CI). The Z test for overall effect shows significance ($P = .01$). The χ^2 -test indicates reduced heterogeneity ($P = .16$, $I^2 = 39\%$); I^2 , a measure of variability expressed in %

September 24, 2019

bioRxiv preprint doi: <https://doi.org/10.1101/2020.05.27.20101196>; this version posted June 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

“interleukin”, “IL-18”, “cytokine”, “polymorphism”, “allograft” and “kidney transplantation”

Identification

MEDLINE / PubMed,
Google Scholar, Science
Direct (n = 31)

Additional records
identified through other
sources (n = 8)

Screening

Records remaining (n = 25) following removal of
non-relevant citations as well as duplicates (n = 14)

Eligibility

Abstracts screened (n = 25)

Excluded 18 articles

- Not renal/allograft 11
- Reviews 2
- Not *IL-18* 5

Full-text articles assessed
for eligibility (n = 7)

Excluded 3 because of
insufficient or absent
data

Included

Articles included in the
meta-analysis (n = 4)

